Blurbs

H.C. Wainwright Reaffirms Their Buy Rating on Progenity (PROG)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Progenity (PROGResearch Report), with a price target of $4.00. The company’s shares closed last Monday at $1.61.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -19.1% and a 27.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Progenity is a Moderate Buy with an average price target of $23.00.

See today’s best-performing stocks on TipRanks >>

Progenity’s market cap is currently $263.6M and has a P/E ratio of -0.45.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics, proteomics, and microbiomics. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing.

Read More on PROG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos